• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

干酪乳杆菌对酒精性肝损伤患者脂代谢及肠道微生态的影响。

Effect of Lactobacillus casei on lipid metabolism and intestinal microflora in patients with alcoholic liver injury.

机构信息

Department of Human Nutrition, College of Public Health, Qingdao University, 38 Dengzhou Road, Qingdao, 266021, China.

Department of Clinical Nutrition, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Shandong, 264000, China.

出版信息

Eur J Clin Nutr. 2021 Aug;75(8):1227-1236. doi: 10.1038/s41430-020-00852-8. Epub 2021 Jan 29.

DOI:10.1038/s41430-020-00852-8
PMID:33514869
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8352779/
Abstract

BACKGROUND

The present study aims to investigate the effect of Lactobacillus casei on lipid metabolism and intestinal microflora in patients with alcoholic liver injury.

METHODS

In a double-blind randomized controlled trial, 158 recruited alcoholic liver injury patients were randomized to three treatments for 60 days: low-dose group (LP, n = 58, 100 ml of Lactobacillus casei strain Shirota (LcS)), high-dose group (HP, n = 54, 200 ml of LcS), and positive control group (PC, n = 46, 100 ml of special drinks without active Lactobacillus casei). Another group of 20 healthy people was served as normal control group (NC).

RESULTS

The serum levels of TG and LDLC in the HP group were significantly decreased by 26.56% and 23.83%, respectively than those in the PC group (P < 0.05). After supplementation of Lactobacillus casei, there was a significant increase in the amount of Lactobacillus and Bifidobacterium when compared with the PC group (P < 0.05).

CONCLUSIONS

Supplementation of Lactobacillus casei can improve lipid metabolism and regulate intestinal flora disorders in patients with alcoholic liver injury.

摘要

背景

本研究旨在探讨干酪乳杆菌对酒精性肝损伤患者脂代谢和肠道菌群的影响。

方法

采用双盲随机对照试验,将 158 例酒精性肝损伤患者随机分为 3 组,分别接受 60 天的治疗:低剂量组(LP,n=58,100ml 干酪乳杆菌 Shirota 株(LcS))、高剂量组(HP,n=54,200ml LcS)和阳性对照组(PC,n=46,100ml 无活性干酪乳杆菌的特殊饮料)。另设 20 名健康人作为正常对照组(NC)。

结果

与 PC 组相比,HP 组的血清 TG 和 LDLC 水平分别显著降低了 26.56%和 23.83%(P<0.05)。补充干酪乳杆菌后,与 PC 组相比,乳杆菌和双歧杆菌的数量明显增加(P<0.05)。

结论

补充干酪乳杆菌可改善酒精性肝损伤患者的脂代谢,调节肠道菌群紊乱。

相似文献

1
Effect of Lactobacillus casei on lipid metabolism and intestinal microflora in patients with alcoholic liver injury.干酪乳杆菌对酒精性肝损伤患者脂代谢及肠道微生态的影响。
Eur J Clin Nutr. 2021 Aug;75(8):1227-1236. doi: 10.1038/s41430-020-00852-8. Epub 2021 Jan 29.
2
Effects of Lactobacillus casei on Iron Metabolism and Intestinal Microflora in Rats Exposed to Alcohol and Iron.酒精和铁暴露大鼠中干酪乳杆菌对铁代谢和肠道菌群的影响。
Turk J Gastroenterol. 2022 Jun;33(6):470-476. doi: 10.5152/tjg.2022.21370.
3
Effect of Lactobacillus casei Shirota supplementation on trimethylamine-N-oxide levels in patients with metabolic syndrome: An open-label, randomized study.补充干酪乳杆菌代田株对代谢综合征患者三甲胺-N-氧化物水平的影响:一项开放标签、随机研究。
Atherosclerosis. 2015 Sep;242(1):141-4. doi: 10.1016/j.atherosclerosis.2015.05.005. Epub 2015 Jul 8.
4
The effect of consumption of milk fermented by Lactobacillus casei strain Shirota on the intestinal microflora and immune parameters in humans.干酪乳杆菌代田株发酵乳对人体肠道微生物群和免疫参数的影响。
Eur J Clin Nutr. 1998 Dec;52(12):899-907. doi: 10.1038/sj.ejcn.1600663.
5
A Double-Blind, Randomized Placebo-Controlled Trial of Probiotic Shirota in Stable Cirrhotic Patients.一项双歧杆菌 Shirota 对稳定期肝硬化患者的双盲、随机、安慰剂对照试验。
Nutrients. 2020 Jun 2;12(6):1651. doi: 10.3390/nu12061651.
6
YRL577 combined with plant extracts reduce markers of non-alcoholic fatty liver disease in mice.YRL577与植物提取物联合使用可降低小鼠非酒精性脂肪性肝病的标志物。
Br J Nutr. 2021 May 28;125(10):1081-1091. doi: 10.1017/S0007114520003013. Epub 2020 Jul 28.
7
Effect of supplementation of fermented milk drink containing probiotic Lactobacillus casei Shirota on the concentrations of aflatoxin biomarkers among employees of Universiti Putra Malaysia: a randomised, double-blind, cross-over, placebo-controlled study.含有益生菌干酪乳杆菌代田株的发酵乳饮料补充剂对马来西亚博特拉大学员工黄曲霉毒素生物标志物浓度的影响:一项随机、双盲、交叉、安慰剂对照研究。
Br J Nutr. 2016 Jan 14;115(1):39-54. doi: 10.1017/S0007114515004109. Epub 2015 Oct 22.
8
Probiotic Lactobacillus casei Shirota prevents acute liver injury by reshaping the gut microbiota to alleviate excessive inflammation and metabolic disorders.植物乳杆菌 Shirota 通过重塑肠道微生物群来减轻过度炎症和代谢紊乱,从而预防急性肝损伤。
Microb Biotechnol. 2022 Jan;15(1):247-261. doi: 10.1111/1751-7915.13750. Epub 2021 Jan 25.
9
Probiotic Lactobacillus casei Zhang reduces pro-inflammatory cytokine production and hepatic inflammation in a rat model of acute liver failure.益生菌干酪乳杆菌 Zhang 可减少急性肝衰竭大鼠模型中促炎细胞因子的产生和肝炎症。
Eur J Nutr. 2016 Mar;55(2):821-831. doi: 10.1007/s00394-015-0904-3. Epub 2015 Apr 18.
10
The effects of the Lactobacillus casei strain on obesity in children: a pilot study.干酪乳杆菌菌株对儿童肥胖的影响:一项初步研究。
Benef Microbes. 2017 Aug 24;8(4):535-543. doi: 10.3920/BM2016.0170. Epub 2017 Jun 16.

引用本文的文献

1
Safety and efficacy of probiotics in the treatment of ALD.益生菌治疗酒精性肝病的安全性和有效性。
Medicine (Baltimore). 2025 Aug 8;104(32):e43662. doi: 10.1097/MD.0000000000043662.
2
Targeting gut health: Probiotics as promising therapeutics in alcohol-related liver disease management.针对肠道健康:益生菌作为酒精性肝病管理中有前景的治疗方法。
AIMS Microbiol. 2025 Jun 11;11(2):410-435. doi: 10.3934/microbiol.2025019. eCollection 2025.
3
Unraveling the Gut-Liver-Brain Axis: Microbiome, Inflammation, and Emerging Therapeutic Approaches.解析肠-肝-脑轴:微生物群、炎症及新兴治疗方法
Mediators Inflamm. 2025 Jun 18;2025:6733477. doi: 10.1155/mi/6733477. eCollection 2025.
4
Updated Insights into Probiotic Interventions for Metabolic Syndrome: Mechanisms and Evidence.代谢综合征益生菌干预的最新见解:机制与证据
Probiotics Antimicrob Proteins. 2025 May 7. doi: 10.1007/s12602-025-10554-x.
5
Probiotic mitigates gut hypoperfusion-associated acute gastrointestinal injury in patients undergoing cardiopulmonary bypass: a randomized controlled trial.益生菌减轻体外循环患者肠道低灌注相关的急性胃肠损伤:一项随机对照试验。
BMC Med. 2025 Apr 23;23(1):238. doi: 10.1186/s12916-025-04082-2.
6
The effect of oral nutritional supplementation combined with probiotics on the liver function and intestinal microflora in lung cancer chemotherapy patients through the gut-liver axis.口服营养补充剂联合益生菌通过肠-肝轴对肺癌化疗患者肝功能和肠道微生物群的影响
Sci Rep. 2025 Mar 24;15(1):10063. doi: 10.1038/s41598-025-95005-x.
7
Gut Microbiota as Emerging Players in the Development of Alcohol-Related Liver Disease.肠道微生物群在酒精性肝病发展中成为新的影响因素。
Biomedicines. 2024 Dec 31;13(1):74. doi: 10.3390/biomedicines13010074.
8
L11 and LR: Ameliorate Obesity via AMPK Pathway.L11和LR:通过AMPK途径改善肥胖。
Nutrients. 2024 Dec 24;17(1):4. doi: 10.3390/nu17010004.
9
Liuweizhiji Gegen-Sangshen beverage protects against alcoholic liver disease in mice through the gut microbiota mediated SCFAs/GPR43/GLP-1 pathway.六味枳椇葛参饮料通过肠道微生物群介导的SCFAs/GPR43/GLP-1途径预防小鼠酒精性肝病。
Front Nutr. 2024 Dec 13;11:1495695. doi: 10.3389/fnut.2024.1495695. eCollection 2024.
10
Lactobacillus helveticus attenuates alcoholic liver injury via regulation of gut microecology in mice.瑞士乳杆菌通过调节小鼠肠道微生态减轻酒精性肝损伤。
Microb Biotechnol. 2024 Oct;17(10):e70016. doi: 10.1111/1751-7915.70016.

本文引用的文献

1
Growing burden of alcoholic liver disease in China: A review.中国酒精性肝病负担日益加重:综述。
World J Gastroenterol. 2019 Mar 28;25(12):1445-1456. doi: 10.3748/wjg.v25.i12.1445.
2
Lactobacillus plantarum LC27 and Bifidobacterium longum LC67 mitigate alcoholic steatosis in mice by inhibiting LPS-mediated NF-κB activation through restoration of the disturbed gut microbiota.植物乳杆菌 LC27 和长双歧杆菌 LC67 通过恢复紊乱的肠道微生物群来抑制 LPS 介导的 NF-κB 激活,从而减轻小鼠的酒精性脂肪变性。
Food Funct. 2018 Aug 15;9(8):4255-4265. doi: 10.1039/c8fo00252e.
3
Protective Effect of Aplysin Supplementation on Intestinal Permeability and Microbiota in Rats Treated with Ethanol and Iron.阿朴脂素补充对乙醇和铁处理大鼠肠道通透性和微生物群的保护作用。
Nutrients. 2018 May 27;10(6):681. doi: 10.3390/nu10060681.
4
[Guidelines of prevention and treatment for alcoholic liver disease: a 2018 update].[酒精性肝病防治指南:2018年更新版]
Zhonghua Gan Zang Bing Za Zhi. 2018 Mar 20;26(3):188-194. doi: 10.3760/cma.j.issn.1007-3418.2018.03.007.
5
Microbiota and the liver.肠道菌群与肝脏。
Liver Transpl. 2018 Apr;24(4):539-550. doi: 10.1002/lt.25008.
6
Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in mice.调节肠道胆汁酸/法尼醇 X 受体/成纤维细胞生长因子 15 轴可改善小鼠的酒精性肝病。
Hepatology. 2018 Jun;67(6):2150-2166. doi: 10.1002/hep.29676. Epub 2018 Apr 16.
7
Alcoholic Liver Disease: Pathogenesis and Current Management.酒精性肝病:发病机制与当前治疗
Alcohol Res. 2017;38(2):147-161.
8
Gut microbiota and the liver.肠道微生物群与肝脏
Minerva Gastroenterol Dietol. 2017 Dec;63(4):385-398. doi: 10.23736/S1121-421X.17.02375-3.
9
Pathophysiology and Management of Alcoholic Liver Disease: Update 2016.酒精性肝病的病理生理学与管理:2016年更新
Gut Liver. 2017 Mar 15;11(2):173-188. doi: 10.5009/gnl16477.
10
Pathogenesis of Alcoholic Liver Disease.酒精性肝病的发病机制
Clin Liver Dis. 2016 Aug;20(3):445-56. doi: 10.1016/j.cld.2016.02.004. Epub 2016 Mar 28.